Factors associated with prognosis and treatment failure in children with acute lymphoblastic leukemia.
10.7499/j.issn.1008-8830.2409008
- Author:
Meng-Meng YIN
1
;
Qun HU
1
;
Ai-Guo LIU
1
;
Ya-Qin WANG
1
;
Ai ZHANG
1
Author Information
1. Department of Pediatric Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
- Publication Type:Journal Article
- Keywords:
Acute lymphoblastic leukemia;
Child;
Prognosis;
Risk factor;
Treatment failure
- MeSH:
Humans;
Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy*;
Male;
Female;
Child;
Child, Preschool;
Retrospective Studies;
Prognosis;
Treatment Failure;
Adolescent;
Infant;
Risk Factors
- From:
Chinese Journal of Contemporary Pediatrics
2025;27(3):308-314
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVES:To explore the factors related to prognosis and treatment failure in children with acute lymphoblastic leukemia (ALL).
METHODS:A retrospective study was conducted to collect and analyze clinical data of ALL children admitted to the Department of Pediatric Hematology at Tongji Hospital, Huazhong University of Science and Technology, from January 2012 to December 2019, with follow-up until June 2024.
RESULTS:A total of 341 children with ALL were included. Among the 69 children with treatment failure, 55 (80%) experienced relapse, while 14 (20%) had non-relapse-related deaths, and no secondary tumors were observed. Initial WBC count ≥50×109/L, positive minimal residual disease, and severe adverse events were identified as independent risk factors for treatment failure (P<0.05). Among the 55 relapsed patients, early relapses were predominant (36%), and the primary site of relapse was the bone marrow (56%). Immunophenotyping (P=0.009), initial WBC count (P=0.011), and fusion genes (P=0.040) were associated with the timing of relapse. High-risk status, T-cell ALL, relapse, and severe adverse events were independent risk factors affecting long-term survival (P<0.05).
CONCLUSIONS:The prognosis of children with ALL is related to risk stratification, immunophenotyping, relapse status, and occurrence of severe adverse events. Among these factors, relapse is the primary cause of treatment failure. Actively preventing relapse may reduce the treatment failure rate and improve long-term survival.
